Concepts (303)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hepatitis B | 18 | 2021 | 159 | 3.110 |
Why?
|
| Hepatitis B virus | 12 | 2020 | 136 | 2.730 |
Why?
|
| Hepacivirus | 10 | 2023 | 241 | 1.420 |
Why?
|
| Hepatitis C | 9 | 2023 | 364 | 1.300 |
Why?
|
| DNA, Viral | 15 | 2020 | 479 | 1.190 |
Why?
|
| HIV-1 | 15 | 2002 | 463 | 1.110 |
Why?
|
| Liver Failure, Acute | 2 | 2016 | 87 | 0.930 |
Why?
|
| Blood Donors | 5 | 2011 | 62 | 0.910 |
Why?
|
| Insulin Resistance | 2 | 2023 | 639 | 0.900 |
Why?
|
| Hepatitis B Surface Antigens | 9 | 2017 | 52 | 0.890 |
Why?
|
| RNA, Viral | 11 | 2011 | 539 | 0.880 |
Why?
|
| Viral Load | 6 | 2017 | 381 | 0.730 |
Why?
|
| Transfusion Reaction | 4 | 2011 | 37 | 0.690 |
Why?
|
| Hepatitis B, Chronic | 4 | 2020 | 82 | 0.670 |
Why?
|
| Infectious Disease Transmission, Vertical | 3 | 2015 | 236 | 0.590 |
Why?
|
| Antiviral Agents | 5 | 2021 | 743 | 0.580 |
Why?
|
| Hepatitis B Vaccines | 5 | 2021 | 41 | 0.500 |
Why?
|
| Thymidine | 1 | 2015 | 54 | 0.490 |
Why?
|
| Blood Transfusion | 3 | 2009 | 304 | 0.480 |
Why?
|
| Jaundice | 1 | 2014 | 27 | 0.470 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2014 | 106 | 0.440 |
Why?
|
| HIV Infections | 12 | 2002 | 1852 | 0.410 |
Why?
|
| Hepatitis A | 2 | 2007 | 32 | 0.410 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2015 | 438 | 0.410 |
Why?
|
| Models, Statistical | 1 | 2014 | 470 | 0.390 |
Why?
|
| Polymerase Chain Reaction | 9 | 2011 | 1584 | 0.380 |
Why?
|
| Hepatitis A Vaccines | 3 | 2007 | 10 | 0.340 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 3 | 2001 | 70 | 0.330 |
Why?
|
| Infectious Disease Incubation Period | 1 | 2009 | 7 | 0.320 |
Why?
|
| Algorithms | 2 | 2021 | 1598 | 0.320 |
Why?
|
| Autophagy | 1 | 2012 | 390 | 0.320 |
Why?
|
| Homeostasis | 1 | 2012 | 683 | 0.300 |
Why?
|
| Glucose | 1 | 2012 | 875 | 0.290 |
Why?
|
| Insulin | 1 | 2012 | 1200 | 0.280 |
Why?
|
| Hepatitis B Antibodies | 4 | 2017 | 24 | 0.280 |
Why?
|
| Humans | 60 | 2023 | 123103 | 0.280 |
Why?
|
| Liver | 8 | 2021 | 1734 | 0.250 |
Why?
|
| Molecular Sequence Data | 10 | 2013 | 3867 | 0.250 |
Why?
|
| Genome, Viral | 2 | 1998 | 170 | 0.250 |
Why?
|
| Public Health | 1 | 2007 | 259 | 0.250 |
Why?
|
| Herpesvirus 6, Human | 4 | 1995 | 58 | 0.250 |
Why?
|
| Genes, Viral | 2 | 2017 | 183 | 0.240 |
Why?
|
| Herpesviridae Infections | 4 | 1995 | 142 | 0.230 |
Why?
|
| Specimen Handling | 2 | 1997 | 140 | 0.230 |
Why?
|
| HIV | 6 | 2011 | 179 | 0.230 |
Why?
|
| Beclin-1 | 1 | 2023 | 26 | 0.230 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2023 | 58 | 0.220 |
Why?
|
| Viral Hepatitis Vaccines | 4 | 1997 | 20 | 0.200 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2023 | 165 | 0.200 |
Why?
|
| Eye Infections, Viral | 2 | 1992 | 28 | 0.200 |
Why?
|
| Viral Regulatory and Accessory Proteins | 2 | 2020 | 38 | 0.190 |
Why?
|
| West Nile Fever | 1 | 2003 | 139 | 0.190 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2023 | 426 | 0.180 |
Why?
|
| Trans-Activators | 2 | 2020 | 809 | 0.180 |
Why?
|
| HIV Seropositivity | 4 | 1995 | 116 | 0.170 |
Why?
|
| Signal Transduction | 1 | 2012 | 4493 | 0.170 |
Why?
|
| Antigen-Antibody Complex | 2 | 1997 | 64 | 0.170 |
Why?
|
| Hepatitis C, Chronic | 3 | 2009 | 323 | 0.170 |
Why?
|
| Skin Diseases | 1 | 2021 | 124 | 0.170 |
Why?
|
| Viral Proteins | 1 | 2001 | 349 | 0.160 |
Why?
|
| Acquired Immunodeficiency Syndrome | 5 | 1994 | 232 | 0.160 |
Why?
|
| China | 2 | 2017 | 241 | 0.160 |
Why?
|
| Amino Acid Sequence | 5 | 2013 | 2695 | 0.160 |
Why?
|
| Recombinant Proteins | 4 | 2017 | 1386 | 0.160 |
Why?
|
| Multiprotein Complexes | 1 | 2020 | 207 | 0.160 |
Why?
|
| Organoids | 1 | 2021 | 277 | 0.150 |
Why?
|
| Hepatitis Viruses | 1 | 1998 | 2 | 0.150 |
Why?
|
| Host-Pathogen Interactions | 1 | 2020 | 249 | 0.150 |
Why?
|
| Genotype | 4 | 2017 | 2533 | 0.150 |
Why?
|
| Hepatitis C Antibodies | 2 | 1997 | 21 | 0.150 |
Why?
|
| Hepatitis, Viral, Human | 1 | 1998 | 44 | 0.150 |
Why?
|
| Pichia | 1 | 2017 | 56 | 0.140 |
Why?
|
| Genetic Variation | 2 | 2007 | 1479 | 0.140 |
Why?
|
| Carcinogenesis | 1 | 2020 | 328 | 0.140 |
Why?
|
| Intestines | 1 | 2021 | 570 | 0.140 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 642 | 0.140 |
Why?
|
| Leukocytes, Mononuclear | 3 | 1996 | 324 | 0.140 |
Why?
|
| Stem Cells | 1 | 2021 | 701 | 0.130 |
Why?
|
| Proviruses | 1 | 1996 | 17 | 0.130 |
Why?
|
| Hepatocytes | 2 | 2020 | 225 | 0.130 |
Why?
|
| Erythrocyte Membrane | 1 | 1995 | 23 | 0.120 |
Why?
|
| CD4 Antigens | 1 | 1995 | 56 | 0.120 |
Why?
|
| Hepatitis A Virus, Human | 1 | 1995 | 9 | 0.120 |
Why?
|
| Interferon-alpha | 2 | 2007 | 221 | 0.120 |
Why?
|
| Erythrocytes | 1 | 1995 | 206 | 0.120 |
Why?
|
| Cellular Senescence | 1 | 1995 | 162 | 0.110 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1909 | 0.110 |
Why?
|
| Meckel Diverticulum | 1 | 1992 | 10 | 0.100 |
Why?
|
| Conserved Sequence | 1 | 1993 | 293 | 0.100 |
Why?
|
| Liver Cirrhosis | 1 | 1999 | 823 | 0.100 |
Why?
|
| Glycogen Synthase | 1 | 2012 | 5 | 0.100 |
Why?
|
| Glycogen Synthase Kinases | 1 | 2012 | 6 | 0.100 |
Why?
|
| Viremia | 4 | 1998 | 126 | 0.100 |
Why?
|
| Viral Envelope Proteins | 1 | 2013 | 150 | 0.100 |
Why?
|
| Ibuprofen | 1 | 1992 | 42 | 0.100 |
Why?
|
| Models, Biological | 2 | 2020 | 1442 | 0.100 |
Why?
|
| Mutant Proteins | 1 | 2012 | 112 | 0.100 |
Why?
|
| Disease Transmission, Infectious | 2 | 2011 | 83 | 0.100 |
Why?
|
| Cell Line | 4 | 2012 | 2771 | 0.100 |
Why?
|
| Adult | 12 | 2017 | 29009 | 0.100 |
Why?
|
| Epitopes | 1 | 1993 | 429 | 0.100 |
Why?
|
| Base Sequence | 5 | 1995 | 3091 | 0.100 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 2055 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2020 | 938 | 0.090 |
Why?
|
| Xenotropic murine leukemia virus-related virus | 1 | 2011 | 2 | 0.090 |
Why?
|
| Amino Acid Substitution | 1 | 2012 | 393 | 0.090 |
Why?
|
| Corneal Diseases | 1 | 1992 | 101 | 0.090 |
Why?
|
| Female | 14 | 2017 | 65514 | 0.090 |
Why?
|
| Quality Assurance, Health Care | 1 | 1992 | 206 | 0.090 |
Why?
|
| Sensitivity and Specificity | 7 | 1998 | 2011 | 0.090 |
Why?
|
| Pregnancy | 7 | 2015 | 7138 | 0.090 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 1992 | 223 | 0.090 |
Why?
|
| Retinal Diseases | 1 | 1992 | 172 | 0.080 |
Why?
|
| AIDS-Related Complex | 1 | 1989 | 2 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2020 | 1311 | 0.080 |
Why?
|
| Hemophilia A | 2 | 2004 | 20 | 0.080 |
Why?
|
| Alanine Transaminase | 1 | 2009 | 150 | 0.080 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2009 | 62 | 0.080 |
Why?
|
| Donor Selection | 1 | 2009 | 52 | 0.080 |
Why?
|
| Male | 15 | 2015 | 60129 | 0.080 |
Why?
|
| Transcription, Genetic | 2 | 1995 | 1702 | 0.080 |
Why?
|
| Immunity, Herd | 1 | 2007 | 12 | 0.070 |
Why?
|
| Carrier State | 1 | 2008 | 76 | 0.070 |
Why?
|
| Lymphocytes | 1 | 1989 | 402 | 0.070 |
Why?
|
| Mutation | 2 | 2017 | 5767 | 0.070 |
Why?
|
| Ribavirin | 1 | 2007 | 79 | 0.070 |
Why?
|
| Reproducibility of Results | 4 | 1998 | 2840 | 0.070 |
Why?
|
| Evaluation Studies as Topic | 2 | 1998 | 256 | 0.070 |
Why?
|
| Interferons | 1 | 2007 | 122 | 0.070 |
Why?
|
| Lamivudine | 1 | 2006 | 25 | 0.070 |
Why?
|
| Organophosphonates | 1 | 2006 | 19 | 0.070 |
Why?
|
| Drug Resistance, Viral | 1 | 2006 | 44 | 0.070 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2006 | 34 | 0.070 |
Why?
|
| Guanine | 1 | 2006 | 60 | 0.070 |
Why?
|
| Reference Standards | 2 | 1998 | 239 | 0.060 |
Why?
|
| Immunization, Secondary | 2 | 2021 | 104 | 0.060 |
Why?
|
| Time Factors | 4 | 2007 | 6219 | 0.060 |
Why?
|
| Adenine | 1 | 2006 | 100 | 0.060 |
Why?
|
| Liver Diseases | 2 | 2003 | 363 | 0.060 |
Why?
|
| HIV Antibodies | 4 | 1994 | 69 | 0.060 |
Why?
|
| Parvovirus B19, Human | 1 | 2004 | 30 | 0.060 |
Why?
|
| Middle Aged | 5 | 2017 | 25992 | 0.060 |
Why?
|
| Drug Contamination | 1 | 2004 | 36 | 0.060 |
Why?
|
| Parvoviridae Infections | 1 | 2004 | 36 | 0.060 |
Why?
|
| Factor VIII | 1 | 2004 | 44 | 0.060 |
Why?
|
| Range of Motion, Articular | 1 | 2004 | 73 | 0.060 |
Why?
|
| Preventive Medicine | 1 | 2003 | 22 | 0.050 |
Why?
|
| Virus Replication | 3 | 2020 | 603 | 0.050 |
Why?
|
| Antigens, Viral | 3 | 1995 | 435 | 0.050 |
Why?
|
| Hepatitis B Antigens | 2 | 1993 | 10 | 0.050 |
Why?
|
| Virus Cultivation | 2 | 2001 | 76 | 0.050 |
Why?
|
| Kidney Transplantation | 1 | 1988 | 630 | 0.050 |
Why?
|
| Cytomegalovirus | 2 | 1995 | 269 | 0.050 |
Why?
|
| False Positive Reactions | 3 | 1998 | 145 | 0.050 |
Why?
|
| Water Supply | 1 | 2002 | 25 | 0.050 |
Why?
|
| Hygiene | 1 | 2002 | 24 | 0.050 |
Why?
|
| Cells, Cultured | 3 | 2021 | 3040 | 0.050 |
Why?
|
| Infant, Newborn | 7 | 2002 | 8106 | 0.050 |
Why?
|
| History, 21st Century | 1 | 2003 | 269 | 0.050 |
Why?
|
| Gene Expression Regulation, Viral | 2 | 1992 | 132 | 0.050 |
Why?
|
| Enterohepatic Circulation | 1 | 2021 | 10 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2003 | 381 | 0.050 |
Why?
|
| Dermatologists | 1 | 2021 | 3 | 0.050 |
Why?
|
| Serial Passage | 1 | 2001 | 19 | 0.050 |
Why?
|
| Glycosylation | 1 | 2001 | 114 | 0.050 |
Why?
|
| HIV Core Protein p24 | 3 | 1995 | 12 | 0.040 |
Why?
|
| Hepatitis Antibodies | 2 | 1997 | 6 | 0.040 |
Why?
|
| Hep G2 Cells | 1 | 2020 | 88 | 0.040 |
Why?
|
| Infant | 7 | 2007 | 12357 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2001 | 715 | 0.040 |
Why?
|
| Morbidity | 1 | 2020 | 241 | 0.040 |
Why?
|
| Stomach | 1 | 2021 | 272 | 0.040 |
Why?
|
| Zidovudine | 2 | 2002 | 22 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2001 | 790 | 0.040 |
Why?
|
| Genes, gag | 2 | 1995 | 7 | 0.040 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 1998 | 53 | 0.040 |
Why?
|
| Hepatovirus | 1 | 1997 | 17 | 0.040 |
Why?
|
| Serotyping | 1 | 1998 | 178 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2020 | 741 | 0.040 |
Why?
|
| Alcoholism | 1 | 1999 | 230 | 0.040 |
Why?
|
| Polysaccharide-Lyases | 1 | 1997 | 2 | 0.040 |
Why?
|
| Heparin Lyase | 1 | 1997 | 2 | 0.040 |
Why?
|
| Luminescent Measurements | 1 | 1997 | 57 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 622 | 0.030 |
Why?
|
| RNA Probes | 2 | 1995 | 30 | 0.030 |
Why?
|
| Autoradiography | 2 | 1995 | 71 | 0.030 |
Why?
|
| Alaska | 1 | 1996 | 5 | 0.030 |
Why?
|
| Animals | 3 | 2007 | 33792 | 0.030 |
Why?
|
| Chronic Disease | 2 | 1998 | 1162 | 0.030 |
Why?
|
| Protein Binding | 1 | 2020 | 1741 | 0.030 |
Why?
|
| HIV Antigens | 1 | 1995 | 12 | 0.030 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 1995 | 16 | 0.030 |
Why?
|
| Genes, env | 1 | 1995 | 9 | 0.030 |
Why?
|
| Global Health | 1 | 2020 | 546 | 0.030 |
Why?
|
| Blood Transfusion, Autologous | 1 | 1995 | 34 | 0.030 |
Why?
|
| Laboratories | 2 | 1994 | 83 | 0.030 |
Why?
|
| Kazakhstan | 2 | 2007 | 8 | 0.030 |
Why?
|
| Half-Life | 1 | 1995 | 156 | 0.030 |
Why?
|
| Heparin | 1 | 1997 | 227 | 0.030 |
Why?
|
| United States | 4 | 2007 | 10651 | 0.030 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1995 | 136 | 0.030 |
Why?
|
| HIV Seronegativity | 1 | 1994 | 26 | 0.030 |
Why?
|
| Acute Disease | 1 | 1998 | 1093 | 0.030 |
Why?
|
| Antibodies, Viral | 3 | 2004 | 1138 | 0.030 |
Why?
|
| Immunization Programs | 1 | 1995 | 63 | 0.030 |
Why?
|
| DNA Primers | 1 | 1995 | 660 | 0.030 |
Why?
|
| Hepatitis B e Antigens | 1 | 2013 | 13 | 0.030 |
Why?
|
| Dideoxyadenosine | 1 | 1993 | 3 | 0.030 |
Why?
|
| Immunoglobulin A | 1 | 1994 | 197 | 0.030 |
Why?
|
| Hepatitis D | 1 | 1993 | 3 | 0.030 |
Why?
|
| Risk Factors | 4 | 2009 | 10018 | 0.030 |
Why?
|
| Hemophilia B | 1 | 1993 | 7 | 0.030 |
Why?
|
| Helicobacter Infections | 1 | 2002 | 1257 | 0.030 |
Why?
|
| DNA, Single-Stranded | 1 | 1992 | 73 | 0.030 |
Why?
|
| Serologic Tests | 1 | 1993 | 117 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1993 | 657 | 0.030 |
Why?
|
| Patient Compliance | 1 | 1996 | 464 | 0.030 |
Why?
|
| Virology | 1 | 1992 | 31 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 1995 | 756 | 0.020 |
Why?
|
| Cryopreservation | 1 | 1992 | 82 | 0.020 |
Why?
|
| DNA Probes | 1 | 1992 | 123 | 0.020 |
Why?
|
| Retina | 1 | 1995 | 456 | 0.020 |
Why?
|
| Anticoagulants | 1 | 1997 | 581 | 0.020 |
Why?
|
| Point Mutation | 1 | 2013 | 348 | 0.020 |
Why?
|
| Culture Media | 1 | 1992 | 182 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 1993 | 1688 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2013 | 3234 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 1992 | 261 | 0.020 |
Why?
|
| Professional Competence | 1 | 1992 | 97 | 0.020 |
Why?
|
| DNA | 1 | 1997 | 1588 | 0.020 |
Why?
|
| Hepatitis B Core Antigens | 1 | 2011 | 15 | 0.020 |
Why?
|
| Blood Banks | 1 | 2011 | 12 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 1999 | 1015 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 1994 | 472 | 0.020 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2011 | 65 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 1993 | 518 | 0.020 |
Why?
|
| Hepatitis A Antibodies | 2 | 2002 | 9 | 0.020 |
Why?
|
| Vaccination | 1 | 1996 | 944 | 0.020 |
Why?
|
| Sexual Partners | 1 | 2011 | 85 | 0.020 |
Why?
|
| Cytomegalovirus Infections | 1 | 1992 | 217 | 0.020 |
Why?
|
| Prenatal Exposure Delayed Effects | 1 | 1993 | 226 | 0.020 |
Why?
|
| Child | 5 | 2004 | 24228 | 0.020 |
Why?
|
| Homosexuality | 1 | 1989 | 18 | 0.020 |
Why?
|
| Inclusion Bodies | 1 | 1989 | 48 | 0.020 |
Why?
|
| North America | 1 | 1990 | 239 | 0.020 |
Why?
|
| Gastric Mucosa | 1 | 1992 | 485 | 0.020 |
Why?
|
| Safety | 1 | 2009 | 218 | 0.020 |
Why?
|
| Prognosis | 1 | 1998 | 4512 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 1989 | 211 | 0.020 |
Why?
|
| Phylogeny | 1 | 2011 | 694 | 0.020 |
Why?
|
| Prevalence | 2 | 2007 | 2395 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2002 | 3664 | 0.020 |
Why?
|
| Adolescent | 3 | 2002 | 19094 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 1992 | 771 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 1751 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2007 | 334 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2007 | 218 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2007 | 3369 | 0.020 |
Why?
|
| Graft Survival | 1 | 1988 | 525 | 0.020 |
Why?
|
| Cornea | 1 | 1991 | 645 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 1993 | 1690 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 2847 | 0.010 |
Why?
|
| False Negative Reactions | 2 | 1995 | 89 | 0.010 |
Why?
|
| Predictive Value of Tests | 3 | 1995 | 2112 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2007 | 1138 | 0.010 |
Why?
|
| Patient Selection | 1 | 2007 | 683 | 0.010 |
Why?
|
| In Situ Hybridization | 2 | 1995 | 473 | 0.010 |
Why?
|
| Sex Factors | 1 | 2007 | 1261 | 0.010 |
Why?
|
| Giant Cells | 1 | 2002 | 34 | 0.010 |
Why?
|
| Seroepidemiologic Studies | 1 | 2002 | 120 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 5039 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2002 | 770 | 0.010 |
Why?
|
| Antibodies, Bacterial | 1 | 2002 | 382 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2006 | 2394 | 0.010 |
Why?
|
| Anti-HIV Agents | 1 | 2002 | 304 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2002 | 862 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2002 | 1413 | 0.010 |
Why?
|
| Age Factors | 1 | 2004 | 2799 | 0.010 |
Why?
|
| Prospective Studies | 1 | 1988 | 6028 | 0.010 |
Why?
|
| Vaccines, Inactivated | 1 | 1997 | 144 | 0.010 |
Why?
|
| Immunization | 1 | 1997 | 308 | 0.010 |
Why?
|
| Retinitis | 1 | 1995 | 17 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1995 | 260 | 0.010 |
Why?
|
| Blood Specimen Collection | 1 | 1994 | 46 | 0.010 |
Why?
|
| Child, Preschool | 2 | 2004 | 13888 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1994 | 246 | 0.010 |
Why?
|
| Fetal Blood | 1 | 1995 | 177 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1993 | 215 | 0.010 |
Why?
|
| Hepatitis Delta Virus | 1 | 1993 | 6 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1995 | 810 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1993 | 192 | 0.010 |
Why?
|
| Helicobacter pylori | 1 | 2002 | 1315 | 0.010 |
Why?
|
| Digoxigenin | 1 | 1992 | 2 | 0.010 |
Why?
|
| Phenotype | 1 | 2002 | 4226 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 1993 | 169 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 1992 | 30 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1993 | 210 | 0.010 |
Why?
|
| Physical Examination | 1 | 1993 | 163 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1991 | 396 | 0.010 |
Why?
|
| Mice | 1 | 2006 | 17537 | 0.000 |
Why?
|
| Blotting, Western | 1 | 1991 | 1100 | 0.000 |
Why?
|
| Aged | 1 | 2002 | 19093 | 0.000 |
Why?
|
| Incidence | 1 | 1991 | 3039 | 0.000 |
Why?
|